白细胞介素-2市场预计到2034年将达到40亿美元，主要由针对IL-2的融合蛋白、单克隆抗体和基因疗法推动，覆盖免疫学、皮肤病学、神经退行性疾病和肿瘤学领域 DelveInsight-动脉网

The Interleukin-2 Market is Set to Reach USD 4 Billion by 2034, Driven by IL-2 Targeting Fusion Proteins, Monoclonal antibodies, and Gene Therapies Across Immunology, Dermatology, Neurodegenerative Disorders, and Oncology | DelveInsight

CISION 等信源发布 2025-03-28 05:31



可切换为仅中文







With the emergence of novel therapies and expanded indications, the United States IL-2 market is projected to reach

随着新疗法的出现和适应症的扩大，美国IL-2市场预计将达到

USD 4 billion

40亿美元

by 2034. Key players driving this expansion include Iovance Biotherapeutics, Eisai, Citius Pharmaceuticals, Nektar Therapeutics, Mural Oncology, Corvus Pharmaceuticals, and Krystal Biotech, among others.

到2034年。推动这一扩展的关键企业包括Iovance生物治疗公司、卫材、Citius制药、Nektar治疗公司、Mural肿瘤学、Corvus制药和Krystal生物技术等。

LAS VEGAS

拉斯维加斯

，

March 27, 2025

2025年3月27日

/PRNewswire/ --

Key Highlights

关键亮点

The total treatment-eligible cases for IL-2 therapies are approximately 13.6 million in the 7MM in 2024. This patient segment comprises an eligible population from 13 leading indications where either IL-2 therapy has been approved or is in clinical trials. The list of indications includes

2024年，在七大市场（7MM）中，IL-2疗法的总治疗适用病例大约为1360万。该患者群体包括来自13个主要适应症的适用人群，这些适应症要么已批准使用IL-2疗法，要么正在进行临床试验。适应症列表包括

Peripheral T-cell lymphoma (PTCL), Cutaneous T-cell lymphoma (CTCL)Non-segmental Vitiligo (NSV), Aplastic Anemia, Amyotrophic Lateral Sclerosis (ALS), Ovarian cancer, Head and neck squamous cell carcinoma (HNSCC), Melanoma, Atopic Dermatitis, Alopecia Areata, Non-small cell lung cancer (NSCLC), and Mucosal Melanoma..

外周T细胞淋巴瘤（PTCL）、皮肤T细胞淋巴瘤（CTCL）、非节段型白癜风（NSV）、再生障碍性贫血、肌萎缩侧索硬化症（ALS）、卵巢癌、头颈部鳞状细胞癌（HNSCC）、黑色素瘤、特应性皮炎、斑秃、非小细胞肺癌（NSCLC）和黏膜黑色素瘤。

In terms of large patient size and volume, leading treatable populations for IL-2 development are NSV, Atopic Dermatitis, Alopecia Areata, NSCLC, and ALS.

在患者规模和数量方面，IL-2开发可治疗的领先人群包括NSV、特应性皮炎、斑秃、非小细胞肺癌（NSCLC）和肌萎缩侧索硬化症（ALS）。

The journey of IL-2 in cancer treatment began in the early 1990s, a time of major advancements in immuno-oncology. Its capacity to stimulate the immune system, particularly T cells and NK cells, positioned IL-2 as a pioneering immunotherapy. The first IL-2-based treatment,

白介素-2（IL-2）在癌症治疗中的旅程始于20世纪90年代初期，这一时期是免疫肿瘤学取得重大进展的阶段。其刺激免疫系统，尤其是T细胞和NK细胞的能力，使IL-2成为一种开创性的免疫疗法。首个基于IL-2的治疗，

PROLEUKIN

普罗莱金

(recombinant human IL-2 or Aldesleukin), received US FDA approval in

（重组人白细胞介素-2或阿地白介素）获得了美国FDA的批准

May 1992

1992年5月

for metastatic renal cell carcinoma (RCC), marking it as the first immunotherapy to provide a novel treatment approach for this aggressive cancer. PROLEUKIN was regarded as a groundbreaking innovation, utilizing the body's immune defenses to combat tumors.

对于转移性肾细胞癌（RCC），这标志着它成为首个为这种侵袭性癌症提供新治疗方式的免疫疗法。PROLEUKIN 被视为一项突破性的创新，利用人体的免疫防御来对抗肿瘤。

Beyond cancer treatment, IL-2 holds promise for

除了癌症治疗，IL-2 还具有潜力用于

autoimmune diseases, inflammatory disorders,

自身免疫疾病，炎症性疾病，

and other conditions.

和其他条件。

The FDA's approval of LYMPHIR (denileukin diftitox-cxdl) in the US in

美国食品药品监督管理局（FDA）批准了LYMPHIR（地尼白介素二氧杂环丁烷-cxdl）

August 2024

2024年8月

for the treatment of adult patients with relapsed or refractory Stage I-III CTCL after at least one prior systemic therapy was a landmark event in this field.

用于治疗既往至少接受过一次系统治疗的复发或难治性I-III期CTCL成年患者是一个具有里程碑意义的事件。

Prominent players in this space include

这一领域的主要参与者包括

Mural Oncology (ALKS 4230 - Nemvaleukin Alfa), Nektar Therapeutics (Rezpegaldesleukin - NKTR-358), Cue Biopharma (CUE-101), Anaveon (ANV419), Krystal Biotech (KB707), Merck Sharp & Dohme (MK-6194), Philogen (Darleukin), Synthekine (STK 012), Assistance Publique Hopitaux de

壁画肿瘤学 (ALKS 4230 - Nemvaleukin Alfa)，Nektar治疗学 (Rezpegaldesleukin - NKTR-358)，Cue生物制药 (CUE-101)，Anaveon (ANV419)，Krystal生物技术 (KB707)，默克夏普与多姆 (MK-6194)，Philogen (Darleukin)，Synthekine (STK 012)，巴黎公立医院集团

Paris

巴黎

/ILTOO Pharma (ILT-101), Innovent Biologics (IBI-363), and Werewolf Therapeutics (WTX-124).

/ILTOO制药（ILT-101）、信达生物（IBI-363）和Werewolf Therapeutics（WTX-124）。

These companies are developing a range of IL-2 therapies to treat various cancers and autoimmune conditions, showcasing the potential of IL-2-based treatments to address a broad spectrum of unmet medical needs.

这些公司正在开发一系列IL-2疗法，以治疗各种癌症和自身免疫疾病，展示了基于IL-2的治疗方法在满足广泛未满足医疗需求方面的潜力。

In terms of revenue estimates, Moderate to severe Atopic dermatitis is the leading indication for IL-2 in the 7MM with total cases of nearly

在收入预测方面，中度至重度特应性皮炎是 IL-2 在七大主要市场（7MM）中的主要适应症，总病例数接近于

39 million

3900万

in 2024, which is expected to increase by 2034 in the 7MM.

在2024年，预计到2034年在7MM中将有所增加。

The eligible cases of NSV in the US comprised nearly

美国符合资格的NSV案例几乎包括了近

1.7 million

170万

in 2024.

2024年。

Learn more about the IL-2 treatment landscape @

了解更多关于IL-2治疗领域的信息 @

Interleukin-2 Therapeutic Landscape

白细胞介素-2 治疗前景

In the years that followed, PROLEUKIN's approval extended to metastatic melanoma in 1998, another challenging cancer to treat. However, despite its revolutionary impact, high-dose IL-2 therapy posed significant obstacles, including severe toxicity, systemic inflammatory responses, and a short half-life.

在随后的几年中，PROLEUKIN 的批准范围于 1998 年扩展到转移性黑色素瘤，这是另一种难以治疗的癌症。然而，尽管其具有革命性的影响，高剂量 IL-2 疗法仍存在严重毒性、系统性炎症反应和半衰期短等重大障碍。

These drawbacks spurred efforts to refine its clinical use, leading to advancements in combination therapies aimed at enhancing IL-2's effectiveness while mitigating its side effects. .

这些缺点促使人们努力改进其临床应用，从而推动了组合疗法的进步，旨在提高IL-2的有效性同时减轻其副作用。

The emergence of immune checkpoint inhibitors in the 2010s further complicated IL-2's clinical role, as these novel therapies provided highly effective treatment alternatives. Nonetheless, IL-2 remained a crucial component of immunotherapy, particularly in combination with checkpoint inhibitors, due to their complementary mechanisms of action.

2010年代免疫检查点抑制剂的出现进一步复杂化了IL-2的临床角色，因为这些新型疗法提供了高效的治疗替代方案。然而，由于其互补的作用机制，IL-2仍然是免疫治疗的重要组成部分，尤其是在与检查点抑制剂联合使用时。

The successful integration of IL-2-based therapies with PD-1/PD-L1 inhibitors revitalized interest in IL-2, offering renewed hope for patients with previously untreatable cancers. .

基于IL-2的疗法与PD-1/PD-L1抑制剂的成功结合重新激发了人们对IL-2的兴趣，为以前无法治疗的癌症患者带来了新的希望。

PROLEUKIN's evolution did not stop with its initial approvals. Continuous research and clinical refinements demonstrated that its therapeutic potential could be maximized through improved delivery methods, combination strategies, and more precise patient selection. These ongoing developments, alongside strategic collaborations, have sustained innovation in IL-2-based therapies, reinforcing their relevance in the evolving landscape of cancer treatment..

PROLEUKIN 的发展并未止步于其最初的获批。持续的研究和临床改进表明，通过改进给药方式、联合策略以及更精确的患者选择，可以最大化其治疗潜力。这些持续的发展以及战略上的合作推动了基于 IL-2 的疗法不断创新，进一步巩固了其在不断发展的癌症治疗领域中的重要地位。

Additionally, in an unexpected turn,

此外，在一个意想不到的转折中，

LYMPHIR

淋巴

(denileukin diftitox-cxdl) has emerged as the next generation of IL‑2 therapy. The FDA's approval of LYMPHIR in the US in

（地尼白介素 diftitox-cxdl）已成为下一代 IL-2 疗法。美国食品药品监督管理局（FDA）在美国批准了 LYMPHIR。

August 2024

2024年8月

for adults with relapsed or refractory Stage I-III CTCL, following at least one prior systemic treatment, was a major milestone in the field. While not a dedicated Treg therapy, LYMPHIR has shown the ability to reduce immunosuppressive Tregs and exert antitumor effects by directly targeting IL-2R-expressing tumors. .

对于接受过至少一种先前全身治疗的复发或难治性I-III期CTCL成人患者而言，是一个领域的重大里程碑。虽然LYMPHIR并非专门的Treg疗法，但它已显示出减少免疫抑制性Tregs的能力，并通过直接靶向表达IL-2R的肿瘤发挥抗肿瘤作用。

Recently, LYMPHIR was added to the NCCN Clinical Practice Guidelines in Oncology with a Category 2A recommendation, highlighting strong, consistent support from the NCCN as a viable treatment option for CTCL patients.

最近，LYMPHIR被添加到NCCN肿瘤学临床实践指南中，并获得了2A类推荐，突显了NCCN对其作为CTCL患者可行治疗方案的强有力且一致的支持。

To know more about FDA-approved IL-2 inhibitors, visit @

要了解更多关于FDA批准的IL-2抑制剂的信息，请访问 @

Approved Interleukin-2 Drugs

批准的白介素-2药物

The IL-2 therapy pipeline remains strong, featuring a diverse array of clinical-stage candidates. Beyond cancer treatments, several therapies for autoimmune diseases are also under investigation. Advancements in technology are shaping the IL-2 therapy landscape, with efforts focused on reducing toxicity, enhancing receptor specificity, and integrating with other immunotherapies such as checkpoint inhibitors.

IL-2治疗的研发管线依然强劲，涵盖多种处于临床阶段的候选药物。除了癌症治疗，还有若干针对自身免疫性疾病的疗法正在研究中。技术的进步正在塑造IL-2治疗的前景，研究重点包括降低毒性、增强受体特异性，以及与检查点抑制剂等其他免疫疗法的结合。

As the pipeline matures, IL-2-based therapies are poised to revolutionize the treatment of cancer, autoimmune conditions, and inflammatory disorders. .

随着这一研发管线的成熟，基于IL-2的疗法有望彻底改变癌症、自身免疫疾病和炎症性疾病的治疗方式。

The emerging IL-2-targeted drug pipeline includes a range of promising candidates, such as

新兴的IL-2靶向药物管线包括一系列有前景的候选药物，例如

Nemvaleukin Alfa

内姆伐芦丁阿尔法

(Mural Oncology),

（壁画肿瘤学），

Soquelitinib

索奎替尼

(Corvus Pharmaceuticals),

（Corvus Pharmaceuticals），

Darleukin

达尔勒金

(Philogen),

(菲洛根),

ILT-101

(ILTOO Pharma),

(ILTOO制药)，

Rezpegaldesleukin

雷珠单抗

(Nektar Therapeutics),

（Nektar Therapeutics），

MK-6194

(Merck Sharp & Dohme LLC),

（默克夏普和多姆公司），

CUE-101

(Cue Biopharma),

（Cue Biopharma），

KB707

(Krystal Biotech),

（Krystal生物技术公司），

IBI-363

(Innovent Biologics), and others.

（信达生物）和其他公司。

Discover which therapies are expected to grab major IL-2 market share @

发现哪些疗法有望占据主要的IL-2市场份额 @

Interleukin-2 Market Report

白细胞介素2市场报告

Nemvaleukin alfa

内姆瓦勒金阿尔法

, developed by

，由开发

Mural Oncology

壁画肿瘤学

, is an emerging therapy with significant potential. This recombinant fusion protein functions as an IL-2 receptor agonist, selectively stimulating immune cells within the tumor microenvironment while limiting systemic activation. By doing so, ALKS 4230 seeks to enhance anti-tumor immunity while mitigating the toxicity commonly associated with high-dose IL-2.

是一种具有显著潜力的新兴疗法。这种重组融合蛋白作为IL-2受体激动剂，能够选择性地刺激肿瘤微环境中的免疫细胞，同时限制系统性激活。通过这种方式，ALKS 4230旨在增强抗肿瘤免疫力，同时减轻通常与高剂量IL-2相关的毒性。

This targeted approach has demonstrated promise in multiple cancers, including melanoma, mucosal melanoma, and platinum-resistant ovarian cancer (PROC)..

这种有针对性的方法在多种癌症中显示出希望，包括黑色素瘤、粘膜黑色素瘤和铂耐药卵巢癌（PROC）。

The ability to direct immune activation specifically to the tumor site marks a major advancement in IL-2-based therapies, making them more precise and effective. As per Mural Oncology's latest presentation in

将免疫激活精准导向肿瘤部位的能力标志着基于IL-2的疗法取得了重大进步，使其更加精确和有效。根据Mural Oncology的最新展示，

November 2024

2024年11月

, interim overall survival data for the PROC cohort (ARTISTRY-7) is expected by late Q1 or early Q2 2025, while top-line results for mucosal melanoma (ARTISTRY-6, Cohort 2) are anticipated in Q2 2025. These upcoming data readouts could provide critical insights that may reshape the treatment landscape.

预计PROC队列（ARTISTRY-7）的中期总生存数据将在2025年第一季度末或第二季度初公布，而黏膜黑色素瘤（ARTISTRY-6，队列2）的初步结果预计将在2025年第二季度发布。这些即将到来的数据可能提供关键见解，有望重塑治疗格局。

ALKS 4230 has also garnered key regulatory designations that underscore its potential to expedite its path toward commercialization and reach a market of nearly .

ALKS 4230 还获得了关键的监管资格认定，这些认定强调了其加快商业化进程并进入一个近似的市场的潜力。

USD 140 million

1.4亿美元

by 2034.

到2034年。

Soquelitinib

索喹替尼

is an experimental oral small-molecule drug designed to selectively inhibit IL-2-inducible T-cell kinase (ITK), an enzyme primarily found in T cells that contributes to T-cell and natural killer cell immune function. This novel therapy is being evaluated for moderate-to-severe atopic dermatitis (Phase I) and relapsed/refractory peripheral T-cell lymphoma (PTCL) (Phase III). .

是一种实验性口服小分子药物，旨在选择性抑制IL-2诱导的T细胞激酶（ITK），这种酶主要存在于T细胞中，对T细胞和自然杀伤细胞的免疫功能有重要作用。这种新型疗法正在评估用于中度至重度特应性皮炎（I期）和复发/难治性外周T细胞淋巴瘤（PTCL）（III期）。

在

August 2024

2024年8月

, the U.S. FDA granted

，美国食品药品监督管理局（FDA）授予

Fast Track Designation (FTD)

快速通道指定 (FTD)

for relapsed/refractory PTCL after at least two prior systemic treatments, while in

对于复发性/难治性PTCL，在至少两次先前的全身治疗后，而

February 2024

2024年2月

, it received

，它收到了

Orphan Drug Designation (ODD)

孤儿药认定 (ODD)

for T-cell lymphoma. Early-stage data from

针对T细胞淋巴瘤。早期数据来自

December 2024

2024年12月

for atopic dermatitis showed promising results, with final outcomes anticipated in the first half of 2025, whereas its first launch is expected in PTCL by 2027 in the US. Combining both PTCL and atopic dermatitis, it is expected to reach a market of approximately

针对特应性皮炎的研究显示出令人鼓舞的结果，最终结果预计在2025年上半年出炉，而其首次在美国的PTCL领域上市预计将在2027年。结合PTCL和特应性皮炎，预计将达到一个大约的市场规模。

USD 360 million

3.6亿美元

by 2034.

到2034年。

Rezpegaldesleukin (NKTR-358)

雷兹培加尔德斯勒金（NKTR-358）

, a recombinant protein developed by Nektar Therapeutics, represents a significant advancement in treating autoimmune diseases. This innovative therapy targets T-regulatory cells (Tregs) through the IL-2 pathway and is being studied in Phase II trials for moderate-to-severe atopic dermatitis and severe alopecia areata.

，由Nektar Therapeutics开发的一种重组蛋白，代表了治疗自身免疫疾病的重大进展。这种创新疗法通过IL-2通路靶向T调节细胞（Tregs），目前正在针对中重度特应性皮炎和重度斑秃进行II期临床试验。

Nektar anticipates topline results in the first and second halves of 2025 for these indications. Offering a more targeted and less toxic method for managing inflammation, Rezpegaldesleukin's self-administered subcutaneous injection further adds to its appeal, with projections for a market size of approximately .

Nektar预计这些适应症的初步结果将分别在2025年上半年和下半年出炉。Rezpegaldesleukin的自我皮下注射提供了一种更有针对性且毒性更小的炎症管理方法，进一步增加了其吸引力，并预计市场规模将达到约。

USD 930 million

9亿3000万美元

by 2034.

到2034年。

ILT-101

is a pre-prepared injectable liquid formulation of low-dose IL-2, supplied in vials and tailored to meet patient needs. It has been developed to treat various conditions, including autoimmune and inflammatory diseases, as well as specific central nervous system disorders. ILTOO Pharma is in a strong position to pursue regulatory approval and has already made notable advancements.

是一种预先制备的低剂量IL-2注射液制剂，以小瓶供应，并根据患者需求量身定制。它被开发用于治疗多种疾病，包括自身免疫和炎症性疾病，以及特定的中枢神经系统疾病。ILTOO制药公司具备强大的实力来寻求监管批准，并已取得显著进展。

Future updates will share details on the company's progress. At present, the company is prioritizing compassionate use access for patients who were part of the clinical trial..

未来的更新将会分享公司进展的细节。目前，公司正在优先为曾参与临床试验的患者提供同情用药途径。

Krystal Biotech's KB707

Krystal生物技术公司的KB707

is a groundbreaking gene therapy designed to deliver IL-2 and IL-12 directly to tumors. The company, known for developing VYJUVEK—the first approved topical gene therapy for dystrophic epidermolysis bullosa in May 2023—is now exploring two administration methods for KB707: intratumoral injection for metastatic melanoma and inhalation for advanced NSCLC.

是一种突破性的基因疗法，旨在将IL-2和IL-12直接递送到肿瘤。该公司因在2023年5月开发了首个获批用于营养不良性大疱性表皮松解症的局部基因疗法VYJUVEK而闻名，目前正探索KB707的两种给药方式：针对转移性黑色素瘤的肿瘤内注射和针对晚期非小细胞肺癌的吸入方式。

The therapy has received .

该疗法已获得批准。

Fast Track Designation (FTD)

快速通道指定 (FTD)

for both indications. Early clinical trials have shown promising outcomes, particularly in NSCLC, where post-anti-PD-1 patients demonstrated a 27% overall response rate (ORR) and 73% disease control rate (DCR) in monotherapy trials. KB707 highlights the potential of targeted gene therapies to revolutionize cancer treatment by providing localized, potent immune responses with reduced side effects..

对于两种适应症均是如此。早期临床试验显示出令人鼓舞的结果，尤其是在非小细胞肺癌（NSCLC）中，接受抗PD-1治疗后的患者在单药治疗试验中表现出27%的总体缓解率（ORR）和73%的疾病控制率（DCR）。KB707突显了靶向基因疗法通过提供局部、强效的免疫反应并减少副作用，从而彻底改变癌症治疗的潜力。

Similarly,

同样，

Cue Biopharma's CUE-101

Cue Biopharma的CUE-101

represents a significant innovation in IL-2-based therapies, specifically targeting the HPV16 antigen in head and neck squamous cell carcinoma (HNSCC). In

代表了基于IL-2疗法的重大创新，特别针对头颈部鳞状细胞癌（HNSCC）中的HPV16抗原。在

October 2022

2022年10月

, the FDA granted Fast Track Designation to CUE-101 for treating HPV16+ refractory/metastatic HNSCC, both as a monotherapy and in combination with KEYTRUDA. By combining IL-2 replacement with precise antigen presentation, CUE-101 enhances tumor targeting and strengthens the anti-cancer immune response.

美国食品药品监督管理局（FDA）授予CUE-101快速通道资格，用于治疗HPV16阳性难治性/转移性头颈部鳞状细胞癌（HNSCC），既可作为单药治疗，也可与KEYTRUDA联合使用。通过结合白介素-2替代疗法和精准的抗原呈递，CUE-101增强了肿瘤靶向性并加强了抗癌免疫反应。

Currently, in clinical trials, the therapy has shown promising results, especially when paired with immune checkpoint inhibitors like KEYTRUDA, and is projected to reach a market value of approximately .

目前，在临床试验中，该疗法已显示出令人鼓舞的结果，特别是当与免疫检查点抑制剂如KEYTRUDA联合使用时，预计将达到约市场价值。

USD 370 million

3.7亿美元

by 2034.

到2034年。

Discover more about IL-2 drugs in development @

了解更多关于正在开发的IL-2药物 @

Interleukin-2 Based Therapies Clinical Trials

基于白介素-2的疗法临床试验

Many companies are working on the development of IL-2-based or IL-2-targeting therapies, currently in the early preclinical stage. These include

许多公司正在开发基于IL-2或针对IL-2的疗法，目前处于早期临床前阶段。这些公司包括

Medicenna Therapeutics

Medicenna治疗学

(MDNA223, MDNA209, MDNA113), a collaboration between

（MDNA223，MDNA209，MDNA113），是以下合作成果：

Medicenna Therapeutics and Merck

Medicenna治疗公司和默克公司

(MDNA223),

（MDNA223），

Xilio Therapeutics

西里奥治疗公司

(XTX501),

Shanghai Junshi Biosciences

君实生物

(JS206),

Egle Therapeutics

(EGL001, EGL002, EGL003),

Cue Biopharma

Cue生物制药

(CUE-401),

Iovance Biotherapeutics

伊奥万斯生物治疗公司

(IOV3001), and others.

（IOV3001）和其他。

With the growth of the IL-2-based therapy pipeline, the future looks very promising. The next-generation therapies aim to not only improve survival rates in cancer patients but also address the unmet needs of those with autoimmune diseases. The key feature of these therapies is the ability to precisely modulate the immune system, enhancing its ability to combat disease while minimizing harm..

随着基于IL-2的治疗管道的增长，未来看起来非常有希望。下一代疗法不仅旨在提高癌症患者的存活率，还解决那些患有自身免疫性疾病患者的未满足需求。这些疗法的关键特征是能够精确调节免疫系统，在增强其对抗疾病的能力的同时将伤害降到最低。

The anticipated launch of these emerging therapies are poised to transform the market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the IL-2-based therapies market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth..

这些新兴疗法的预期推出将在未来几年内改变市场格局。随着这些前沿疗法不断成熟并获得监管批准，它们预计将重塑基于IL-2的疗法市场格局，提供新的治疗标准，并为医疗创新和经济增长带来机遇。

As a result, the IL-2 market is set for swift transformation in the near future. Existing therapies such as PROLEUKIN and LYMPHIR are already making notable strides in oncology, while emerging treatments like ALKS 4230, Rezpegaldesleukin, and Soquelitinib are expanding the possibilities for autoimmune diseases and immuno-oncology..

因此，IL-2市场将在不久的将来迎来快速变革。现有的PROLEUKIN和LYMPHIR等疗法已在肿瘤学领域取得了显著进展，而ALKS 4230、Rezpegaldesleukin和Soquelitinib等新兴治疗方案正在拓展自身免疫疾病和免疫肿瘤学的可能性。

DelveInsight estimates that the market size for IL-2-based/targeting therapies in the 7MM is expected to reach an estimated

德尔维洞察估计，基于IL-2/针对IL-2的疗法在七大市场的市场规模预计将达到预估水平。

USD 4 billion

40亿美元

by 2034, reflecting the expanding role of IL-2 in treating both cancer and autoimmune diseases.

到2034年，反映出IL-2在治疗癌症和自身免疫疾病方面日益扩展的作用。

DelveInsight's latest published market report titled as

德尔维洞察最新发布的市场报告标题为

Interleukin-2 Market Size, Target Population, Competitive Landscape & Market Forecast – 2034

白介素-2市场规模、目标人群、竞争格局与市场预测——2034

will help you to discover which market leader is going to capture the largest market share. The report provides comprehensive insights into the IL-2 country-specific treatment guidelines, patient pool analysis, and epidemiology forecast to help understand the key opportunities and assess the market's underlying potential.

将帮助您发现哪个市场领导者将占据最大的市场份额。该报告提供了对IL-2特定国家的治疗指南、患者群体分析和流行病学预测的全面洞察，以帮助理解关键机会并评估市场的潜在潜力。

The IL-2 market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:.

IL-2市场报告提供了2020年至2034年研究期间在7MM中的流行病学分析，分为以下部分：。

Total Cases of Selected Indications

所选适应症的总病例数

Indication-wise Eligible Cases

适应症方面符合条件的病例

Indication-wise Treated Cases

按适应症分类的治疗病例

The report provides an edge while developing business strategies by understanding trends shaping and driving the 7MM IL-2-based therapies market. Highlights include:

该报告通过了解影响和推动七大市场（7MM）IL-2疗法市场的趋势，为制定商业策略提供了优势。亮点包括：

10-year Forecast

10年预测

7MM Analysis

7MM分析

Epidemiology-based Market Forecasting

基于流行病学的市场预测

Historical and Forecasted Market Analysis upto 2034

历史和预测市场分析直至2034年

Emerging Drug Market Uptake

新兴药物市场吸收率

Launch Timelines and Peak Sales Analysis

上市时间表与销售峰值分析

Key Cross Competition Analysis

关键交叉竞争分析

Industry Expert's Opinion

行业专家意见

Access and Reimbursement

获取和报销

Download this IL-2 market report to assess the epidemiology forecasts, understand the patient journeys, know KOLs' opinions about the upcoming treatment paradigms, and determine the factors contributing to the shift in the IL-2 market. Also, stay abreast of the mitigating factors to improve your market position in the IL-2 therapeutic space..

下载这份IL-2市场报告，评估流行病学预测，了解患者旅程，知晓关键意见领袖（KOL）对即将到来的治疗模式的看法，并确定影响IL-2市场变化的因素。同时，紧跟缓解因素，以提升您在IL-2治疗领域的市场地位。

Table of Contents

Key Insights

关键见解

Report Introduction

报告介绍

Executive Summary

执行摘要

Key Events

关键事件

Epidemiology and Market Forecast Methodology

流行病学与市场预测方法论

IL-2 Market Overview at a Glance by Indication in the 7MM

七大市场（7MM）中按适应症划分的IL-2市场概况一览

6.1

Market Share (%) Distribution of IL-2 by Indication in 2028

2028年IL-2按适应症的市场份额（%）分布

6.2

Market Share (%) Distribution of IL-2 by Indication in 2034

2034年IL-2按适应症的市场占有率（%）分布

IL-2 Market Overview at a Glance by Therapies in the 7MM

七大市场（7MM）中按疗法分类的IL-2市场概况一览

7.1

Market Share (%) Distribution of IL-2 by Therapies in 2028

2028年IL-2按治疗分类的市场份额（%）分布

7.2

Market Share (%) Distribution of IL-2 by Therapies in 2034

2034年IL-2按疗法的市场份额（%）分布

Disease Background and Overview

疾病背景与概述

8.1

Introduction

介绍

8.2

Classes of IL-2 receptors

白介素-2受体的分类

8.3

Biology of IL-2

IL-2的生物学

8.3.1

TCR Signaling and IL-2 Production

TCR信号传导和IL-2产生

8.3.2

IL-2R Signaling

IL-2R信号传导

8.3.3

Pleiotropic Action of IL-2

IL-2的多效作用

8.4

IL-2 as a Therapeutic Modality

IL-2作为一种治疗方式

8.4.1

Inhibition of IL-2 Signaling as a Therapeutic Modality

抑制IL-2信号传导作为一种治疗方式

8.5

Potential of IL-2 in the Treatment of Different Indications

IL-2在不同适应症治疗中的潜力

8.6

Challenges

挑战

8.7

Guidelines

指南

Epidemiology and Patient Population

流行病学与患者人群

9.1

Key Findings

主要发现

9.2

Assumptions and Rationale: 7MM

假设与理由：7MM

9.3

Epidemiology Scenario in the 7MM

7MM中的流行病学情景

9.3.1

Total Cases of Selected Indications in the 7MM

七大市场中选定适应症的总病例数

9.3.2

Indication-wise Eligible Cases in the 7MM

7MM中的适应症相关合格病例

9.3.3

Indication-wise Treated Cases in the 7MM

7MM中的按适应症分类的治疗病例

Marketed Drug

上市药物

10.1

Key Cross Competition

关键交叉竞争

10.2

LYMPHIR/REMITORO/E7777/ONTAK (denileukin diftitox): Citius Oncology and Eisai

LYMPHIR/REMITORO/E7777/ONTAK（地尼白介素二氧毒素）：Citius Oncology 和 Eisai 公司

10.2.1

Product Description

产品描述

10.2.2

Regulatory Milestones

监管里程碑

10.2.3

Other Development Activities

其他开发活动

10.2.4

Clinical Development

临床开发

10.2.4.1

Clinical Trial Information

临床试验信息

10.2.5

Safety and Efficacy

安全性与有效性

10.3

PROLEUKIN (aldesleukin): Iovance Biotherapeutics /Clinigen/Novartis

普罗莱金（阿地白介素）：Iovance生物治疗/Clinigen/诺华

十一

Emerging Drugs

新兴药物

11.1

Key Competitors

主要竞争对手

11.2

Nemvaleukin Alfa (ALKS 4230): Mural Oncology

Nemvaleukin Alfa (ALKS 4230): Mural 肿瘤学

11.2.1

Product Description

产品描述

11.2.2

Other Developmental Activities

其他开发活动

11.2.3

Clinical Development

临床开发

11.2.3.1

Clinical Trial Information

临床试验信息

11.2.4

Safety and Efficacy

安全性与有效性

11.3

Soquelitinib (CPI-818): Corvus Pharmaceuticals

11.4

Darleukin (L19IL2): Philogen

达乐金（L19IL2）：菲罗根

11.5

MK-6194: Merck

MK-6194：默克

11.6

Rezpegaldesleukin (REZPEG, NKTR-358, LY3471851): Nektar

雷兹培加德勒金（REZPEG，NKTR-358，LY3471851）：Nektar

11.7

CUE-101: Cue Biopharma

CUE-101：Cue生物制药

11.8

KB707: Krystal Biotech

KB707：Krystal生物技术公司

11.9

ILT-101: ILTOO Pharma

ILT-101：ILTOO制药公司

11.10

IBI363: Innovent

IBI363：信达生物

11.11

REGN7257: Regeneron Pharmaceuticals

REGN7257：再生元制药公司

11.12

Oncoquest-L Vaccine: R2T Biopharma (XEME Biopharma)

Oncoquest-L疫苗：R2T生物制药（XEME生物制药）

11.13

GI-101/GI-101A: GI Innovation, AstraZeneca and Merck (MSD)

GI-101/GI-101A：GI Innovation、阿斯利康和默克（MSD）

11.14

GI-102: GI Innovation and Merck

GI-102：GI创新与默克

11.15

Oncoquest-CLL Vaccine: R2T Biopharma (XEME Biopharma)

Oncoquest-CLL疫苗：R2T生物制药（XEME生物制药）

11.16

SAR444336 (THOR-809): Sanofi

SAR444336 (THOR-809): 赛诺菲

11.17

STK-012: Synthekine

STK-012：合成细胞因子

11.18

BNT152+ BNT153: BioNTech

BNT152+ BNT153：BioNTech

11.19

MDNA11: Medicenna Therapeutics

MDNA11：Medicenna Therapeutics

11.20

TransCon IL-2 β/γ: Ascendis Pharma

TransCon IL-2 β/γ：Ascendis Pharma

11.21

Pegenzileukin/THOR-707 (SAR444245): Sanofi/Synthorx

Pegenzileukin/THOR-707 (SAR444245): 赛诺菲/合成生物学公司

11.22

CUG252: Cugene/AbbVie

CUG252：Cugene/AbbVie

11.23

DK210 (EGFR): Deka Biosciences

DK210（EGFR）：Deka Biosciences

11.24

DF6215: Dragonfly Therapeutics

DF6215：蜻蜓治疗公司

11.25

WTX-124: Werewolf Therapeutics

WTX-124：狼人治疗学

11.26

XTX202: Xilio Therapeutics

XTX202：西里奥治疗公司

11.27

BNZ132-1-40/EQ 101: Bioniz Therapeutics/Equillium

BNZ132-1-40/EQ 101：Bioniz Therapeutics/Equillium

11.28

AB248: Asher Bio

AB248：Asher Bio

11.29

SYNCAR-001 + STK-009: Synthekine

SYNCAR-001 + STK-009：Synthekine

11.30

ANV419: Anaveon

ANV419：Anaveon

11.31

AU-007: Aulos Bioscience

AU-007：奥洛斯生物科学

11.32

SLC-3010: Selecxine/ProBio

SLC-3010: Selecxine/普罗生物

11.33

Eciskafusp alfa (PD1-IL-2v, RG6279): Hoffmann-La Roche

艾西卡福斯帕尔法（PD1-IL-2v，RG6279）：霍夫曼-拉罗氏

11.34

TILT-123: TILT Biotherapeutics

TILT-123：TILT生物治疗公司

IL-2: 7MM analysis

IL-2：7MM分析

12.1

Key Findings

主要发现

12.2

Market Outlook

市场展望

12.3

Conjoint Analysis

联合分析

12.4

Key Market Forecast Assumptions

关键市场预测假设

12.5

Market Size of IL-2 in the 7MM

7MM中IL-2的市场规模

12.6

United States Market Size

美国市场规模

12.6.1

Market Size of IL-2 by Indications in the United States

美国IL-2按适应症划分的市场规模

12.6.2

Market Size by Therapies in the United States

美国按疗法划分的市场规模

12.7

EU4 and the UK Market Size

EU4 和英国市场规模

12.7.1

Market size of IL-2 by Indications in EU4 and the UK

欧盟四大国及英国按适应症划分的IL-2市场规模

12.7.2

Market Size by Therapies in EU4 and the UK

欧盟四大市场和英国的疗法市场规模

12.8

Japan Market Size

日本市场规模

12.8.1

Market size of IL-2 by Indications in Japan

日本按适应症划分的IL-2市场规模

12.8.2

Market Size by Therapies in Japan

日本各疗法市场规模

Unmet Needs

未满足的需求

SWOT Analysis

SWOT分析

KOL Views

KOL观点

Market Access and Reimbursement

市场准入与报销

16.1

United States

美国

16.1.1

Centre for Medicare and Medicaid Services (CMS)

医疗保险和医疗补助服务中心 (CMS)

16.2

EU4 and the UK

EU4 与英国

16.2.1

Germany

德国

16.2.2

France

法国

16.2.3

Italy

意大利

16.2.4

Spain

西班牙

16.2.5

United Kingdom

英国

16.3

Japan

日本

16.3.1

MHLW

厚生劳动省

16.4

Market Access and Reimbursement of IL-2

IL-2的市场准入与报销

Appendix

附录

17.1

Bibliography

参考文献

17.2

Report Methodology

报告方法论

DelveInsight Capabilities

德威尔洞察力能力

Disclaimer

免责声明

About DelveInsight

关于DelveInsight

Related Reports